Topical Midostaurin Composition for Low-Toxicity Melanin Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for skin hyperpigmentation conditions, such as melasma and post-inflammatory hyperpigmentation, are only partially effective and often toxic, causing side effects like loss of skin pigmentation or ochronosis.
Innovation Solution
Topical application of a multi-targeting protein kinase inhibitor, midostaurin, or its pharmaceutically acceptable salt, which targets multiple protein kinases to reduce tyrosinase activity and melanin production, formulated in a topical pharmaceutical composition with specific excipients and carriers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If non-selective toxins (hydroquinone, azelaic acid, kojic acid) are used to reduce tyrosinase activity, then skin pigmentation is reduced, but toxicity and side effects (loss of skin pigmentation, ochronosis) increase
Solution Approach 1:
The patent changes the chemical parameter from non-selective toxins to a multi-targeting protein kinase inhibitor (midostaurin), which selectively inhibits multiple kinases involved in melanogenesis pathways. This parameter change maintains pigmentation reduction efficacy while reducing toxic side effects by targeting specific molecular pathways rather than broadly inhibiting tyrosinase activity
Solution Approach 2:
The patent employs a multi-targeting protein kinase inhibitor that simultaneously inhibits multiple kinase pathways (including PKC, Src, and other kinases involved in melanogenesis) through a single compound. This multi-functional approach reduces melanin production through multiple mechanisms while using one substance, thereby reducing toxicity compared to using multiple separate agents
2Quantity of substance
If current therapies are applied to treat skin hyperpigmentation, then some pigmentation reduction is achieved, but effectiveness is only partial
Solution Approach 1:
The patent uses a multi-targeting protein kinase inhibitor that simultaneously addresses multiple pathways involved in melanogenesis (PKC pathway, Src pathway, and other kinase-mediated pathways). This multi-functional inhibition provides more comprehensive and reliable pigmentation reduction compared to single-target therapies, achieving greater consistency and effectiveness across different types of hyperpigmentation
3Stability of the object's composition
If topical pharmaceutical composition is formulated with multi-targeting protein kinase inhibitor, then chemical stability and efficacy are maintained over time, but formulation complexity increases
Solution Approach 1:
The patent formulates a composite topical pharmaceutical composition that combines the multi-targeting protein kinase inhibitor with specific excipients and delivery systems designed to enhance stability. The composite formulation integrates multiple components (active ingredient, stabilizers, penetration enhancers, and carriers) that work synergistically to maintain chemical stability and efficacy over time while managing the complexity through systematic formulation design
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Reduces melanin amount by at least 25% and tyrosinase activity, with minimal skin irritation and toxicity, compared to hydroquinone, while maintaining chemical stability and efficacy over time.
Implementation Method 1
topically applying a multi-targeting protein kinase inhibitor (e.g., midostaurin) or a salt thereof to a skin of a subject, wherein the skin is associated with a skin-related disease or disorder
Data Source
AI summary
Provided herein are methods of treating a skin-related disease or disorder (such as melasma). Also provided are pharmaceutical compositions of midostaurin or a pharmaceutically acceptable salt thereof formulated for topical administration. Further described are methods for preparing such topical pharmaceutical compositions and methods of using the same for treating a subject.